Denise C. Connolly
Women's Cancer Program
Fox Chase Cancer Center
Denise C. Connolly has not added Biography.
If you are Denise C. Connolly and would like to personalize this page please email our Author Liaison for assistance.
Activation of cancer-specific gene expression by the survivin promoter.
Journal of the National Cancer Institute Apr, 2002 | Pubmed ID: 11929953
Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
Cancer research Mar, 2003 | Pubmed ID: 12649204
Focus on epithelial ovarian cancer.
Cancer cell Jan, 2004 | Pubmed ID: 14749123
Membrane localization of v-ErbB is required but not sufficient for ligand-independent transformation.
Experimental cell research Jun, 2004 | Pubmed ID: 15149858
Pathology of Ovarian Neoplasms in Genetically Modified Mice.
Comparative medicine Feb, 2004 | Pubmed ID: 15382342
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.
Cancer research Mar, 2006 | Pubmed ID: 16510568
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2006 | Pubmed ID: 16533786
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Proceedings of the National Academy of Sciences of the United States of America Nov, 2006 | Pubmed ID: 17088539
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
Cancer research Mar, 2007 | Pubmed ID: 17363557
Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer.
Cancer biology & therapy Nov, 2007 | Pubmed ID: 17986851
Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.
PloS one , 2009 | Pubmed ID: 19172191
NEDD9 promotes oncogenic signaling in mammary tumor development.
Cancer research Sep, 2009 | Pubmed ID: 19738060
Animal models of ovarian cancer.
Cancer treatment and research , 2009 | Pubmed ID: 19763445
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
PloS one , 2009 | Pubmed ID: 20046879
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.
PloS one , 2010 | Pubmed ID: 20422001
Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy.
Translational oncology , 2010 | Pubmed ID: 20563260
Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.
Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.] Jun, 2009 | Pubmed ID: 20634901
Development of a syngeneic mouse model of epithelial ovarian cancer.
Journal of ovarian research , 2010 | Pubmed ID: 20958993
Miscommunication involving 'standard care'. Response to protocol review scenario: specify all medications.
Lab animal Mar, 2011 | Pubmed ID: 21326182
Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents.
Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.] Jun, 2009 | Pubmed ID: 22294392
JoVEについて
Copyright © 2023 MyJoVE Corporation. All rights reserved